Zobrazeno 1 - 10 of 94 pro vyhledávání: '"Fedor Bachmann"'
2
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease
Autor: Lars Hvilsted Rasmussen, Steen Dalby Kristensen, Kurt Huber, Fabrizio Ricci, Gregory Y.H. Lip, João Morais, Dirk Sibbing, Agneta Siegbahn, Freek W.A. Verheugt, Raffaele De Caterina, Jørgen Jespersen, Sigrun Halvorsen, Felicita Andreotti, Jean-Philippe Collet, Colin Baigent, Robert F. Storey, Harald Arnesen, Jeffrey I. Weitz, Lars Wallentin, Steen Elkjær Husted, Fedor Bachmann, Jurriën M. ten Berg
Publikováno v: De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Collet, J-P, Halvorsen, S, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Ricci, F, Sibbing, D, Siegbahn, A, Storey, R F, Ten Berg, J, Verheugt, F W A & Weitz, J I 2016, ' Oral anticoagulants in coronary heart disease (Section IV) : Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 685-711 . https://doi.org/10.1160/TH15-09-0703
Thrombosis and Haemostasis, 115, 4, pp. 685-711
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Collet, J-P, Halvorsen, S, Huber, K, Jespersen, J, Dalby Kristensen, S, Lip, G Y H, Morais, J, Rasmussen, L H, Ricci, F, Sibbing, D, Siegbahn, A, Storey, R F, Ten Berg, J, Verheugt, F W A & Weitz, J I 2016, ' Oral anticoagulants in coronary heart disease (Section IV) : Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 685-711 . https://doi.org/10.1160/TH15-09-0703
Thrombosis and Haemostasis, 115, 685-711
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Collet, J-P, Halvorsen, S, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Ricci, F, Sibbing, D, Siegbahn, A, Storey, R F, Ten Berg, J, Verheugt, F W A & Weitz, J I 2016, ' Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 685-711 . https://doi.org/10.1160/TH15-09-0703
SummaryUntil recently, vitamin K antagonists (VKAs) were the only available oral anticoagulants evaluated for long-term treatment of patients with coronary heart disease (CHD), particularly after an acute coronary syndrome (ACS). Despite efficacy in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2df839339f412ec880dd78b90f94fcce
https://doi.org/10.1160/th15-09-0703
Zobrazit plný text záznamu
3
Current targets of anticoagulants
Autor: Fedor Bachmann
Publikováno v: ESC CardioMed
Anticoagulants are useful agents for the treatment and the prevention of thromboembolic disease that function by diminishing the blood coagulation activity or by reducing the concentration of coagulation factors.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8232d99023fcb8d723f5eff066ef11a9
https://doi.org/10.1093/med/9780198784906.003.0047
Zobrazit plný text záznamu
4
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
Autor: Raffaele De Caterina, Steen Husted, Lars Wallentin, Felicita Andreotti, Harald Arnesen, Fedor Bachmann, Colin Baigent, Kurt Huber, Jørgen Jespersen, Steen Dalby Kristensen, Gregory Y.H. Lip, João Morais, Lars Hvilsted Rasmussen, Agneta Siegbahn, Freek W.A. Verheugt, Jeffrey I. Weitz
Publikováno v: Journal of the American College of Cardiology. 59:1413-1425
Until recently, vitamin K antagonists were the only available oral anticoagulants, but with numerous limitations that prompted the introduction of new oral anticoagulants targeting the single coagulation enzymes thrombin (dabigatran) or factor Xa (ap
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a2068d9a484f32246d3a7fdac685472
https://doi.org/10.1016/j.jacc.2012.02.008
Zobrazit plný text záznamu
7
Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios
Autor: Colin Baigent, Bernard Charbonnier, Desmond J. Fitzgerald, Luis A. García Rodríguez, Guilles Montalescot, Freek W.A. Verheugt, Jozef Vermylen, Raffaele De Caterina, Jan Kvasnicka, Fedor Bachmann, Lars Wallentin, Carlo Patrono, Christopher Bode, Steen Husted, Jack Hirsh
Publikováno v: Revista Española de Cardiología. 57:963-980
Carlo Patrono (Chairperson)* (Italy), Fedor Bachmann (Switzerland), Colin Baigent (UK), Christopher Bode (Germany), Raffaele De Caterina (Italy), Bernard Charbonnier (France), Desmond Fitzgerald (Ireland), Jack Hirsh (Canada), Steen Husted (Denmark),
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b5b0c8c9963b75db7ddb64e0cad559
https://doi.org/10.1016/s0300-8932(04)77225-5
Zobrazit plný text záznamu
8
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease
Autor: Jeffrey I. Weitz, Raffaele De Caterina, Steen Dalby Kristensen, Steen Husted, Gregory Y.H. Lip, Colin Baigent, Fedor Bachmann, Felicita Andreotti, Lars Hvilsted Rasmussen, João Morais, Kurt Huber, Agneta Siegbahn, Jørgen Jespersen, Harald Arnesen, Lars Wallentin, Freek W.A. Verheugt
Publikováno v: De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Huber, K, Jespersen, J, Kristensen, S D, Y.H. Lip, G, Morais, J, Hvilsted Rasmussen, L, Siegbahn, A, W.A. Verheugt, F & Weitz, J I 2013, ' Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 110, no. 6, pp. 1087-1107 . https://doi.org/10.1160/TH13-06-0443
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Siegbahn, A, Verheugt, F W A & Weitz, J I 2013, ' Vitamin K antagonists in heart disease : Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 110, no. 6, pp. 1087-1107 . https://doi.org/10.1160/TH13-06-0443
Thrombosis and Haemostasis, 110, 1087-107
Thrombosis and Haemostasis, 110, 6, pp. 1087-107
Contains fulltext : 126210.pdf (Publisher’s version ) (Closed access) Oral anticoagulants are a mainstay of cardiovascular therapy, and for over 60 years vitamin K antagonists (VKAs) were the only available agents for long-term use. VKAs interfere
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ecbc8dc277d7bedacf602b384f39b48
https://pubmed.ncbi.nlm.nih.gov/24226379
Zobrazit plný text záznamu
9
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease
Autor: Fedor Bachmann, Steen Dalby Kristensen, Steen Elkjær Husted, Felicita Andreotti, Agneta Siegbahn, Colin Baigent, Lars Hvilsted Rasmussen, Gregory Y.H. Lip, R. De Caterina, Freek W.A. Verheugt, João Morais, Kurt Huber, Harald Arnesen, Lars Wallentin, Jeffrey I. Weitz, Jørgen Jespersen
Publikováno v: Thrombosis and Haemostasis, 109, 4, pp. 569-79
Thrombosis and Haemostasis, 109, 569-79
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Siegbahn, A, Verheugt, F W A, Weitz, J I & European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease 2013, ' General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 109, no. 4, pp. 569-79 . https://doi.org/10.1160/TH12-10-0772
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Huber, K, Jespersen, J, Dalby Kristensen, S, Lip, G Y H, Morais, J, Hvilsted Rasmussen, L, Siegbahn, A, Verheugt, F W A & Weitz, J I 2013, ' General mechanisms of coagulation and targets of anticoagulants (Section I) : Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 109, no. 4, pp. 569-579 . https://doi.org/10.1160/TH12-10-0772
SummaryContrary to previous models based on plasma, coagulation processes are currently believed to be mostly cell surface-based, including three overlapping phases: initiation, when tissue factor-expressing cells and microparticles are exposed to pl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121751bef161947a0eff353f676191b7
https://hdl.handle.net/2066/119284
Zobrazit plný text záznamu
10
Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease
Autor: Lars Wallentin, Steen Dalby Kristensen, G Y H Lip, Lars Hvilsted Rasmussen, F. W. A. Verheugt, A. Siegbahn, Kurt Huber, Jeffrey I. Weitz, Steen Elkjær Husted, Felicita Andreotti, Jørgen Jespersen, Fedor Bachmann, João Morais, R. De Caterina, Colin Baigent, Harald Arnesen
Publikováno v: Thrombosis and Haemostasis, 109, 5, pp. 769-86
Thrombosis and Haemostasis, 109, 769-86
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Siegbahn, A, Verheugt, F W A & Weitz, J I 2013, ' Parenteral anticoagulants in heart disease : current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 109, no. 5, pp. 769-86 . https://doi.org/10.1160/TH12-06-0403
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Huber, K, Jespersen, J, Dalby Kristensen, S, Y.H. Lip, G, Morais, J, Hvilsted Rasmussen, L, Siegbahn, A, W.A. Verheugt, F & I. Weitz, J 2013, ' Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) : Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 109, no. 5, pp. 769-786 . https://doi.org/10.1160/TH12-06-0403
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Siegbahn, A, Verheugt, F W A & Weitz, J I 2013, ' Parenteral anticoagulants in heart disease : Current status and perspectives (Section II). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 109, no. 5, pp. 769-86 . https://doi.org/10.1160/TH12-06-0403
SummaryAnticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4eab429e0a251c88ed02bcd71b27ac
https://hdl.handle.net/2066/119164
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje